Gepirone as a 5-HT1A agonist in the treatment of major depression.
Twenty-four patients with major depression were treated in a single-blind design with 25 mg to 75 mg gepirone, a pyrimidinyl piperidinedione analog of buspirone with serotonin1A (5-HT1A) receptor affinity properties. Twenty-four-Item Hamilton Rating Scale for Depression-(HAM-D) scores decreased by 36 percent when mean baseline scores were compared with an endpoint analysis of 6 weeks' gepirone treatment. Several subjects demonstrated marked improvements over baseline. The data are discussed within the context of 5-HT1A receptor desensitization as a potential component of antidepressant treatment.
Rausch
J L
JL
Department of Psychiatry, San Diego VAMC, School of Medicine, University of California, San Diego, La Jolla 92093.
Ruegg
R
R
Moeller
F G
FG
D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D011743:Pyrimidines / Q000627:therapeutic use*; D012701:Serotonin / Q000502:physiology*
D014151:Anti-Anxiety Agents; D011743:Pyrimidines; D012701:Serotonin; C039979:gepirone